MX367914B - Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1. - Google Patents
Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.Info
- Publication number
- MX367914B MX367914B MX2016012668A MX2016012668A MX367914B MX 367914 B MX367914 B MX 367914B MX 2016012668 A MX2016012668 A MX 2016012668A MX 2016012668 A MX2016012668 A MX 2016012668A MX 367914 B MX367914 B MX 367914B
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazolo
- tetrahydro
- derivatives
- substituted
- diazepine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14161950 | 2014-03-27 | ||
| PCT/EP2015/056498 WO2015144799A1 (en) | 2014-03-27 | 2015-03-26 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016012668A MX2016012668A (es) | 2016-12-14 |
| MX367914B true MX367914B (es) | 2019-09-11 |
Family
ID=50389872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012668A MX367914B (es) | 2014-03-27 | 2015-03-26 | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10280170B2 (enExample) |
| EP (1) | EP3129376B1 (enExample) |
| JP (1) | JP6522646B2 (enExample) |
| KR (1) | KR102455519B1 (enExample) |
| CN (1) | CN106164076B (enExample) |
| AU (1) | AU2015238296B2 (enExample) |
| BR (1) | BR112016022105B1 (enExample) |
| CA (1) | CA2940918C (enExample) |
| EA (1) | EA032255B1 (enExample) |
| ES (1) | ES2715676T3 (enExample) |
| IL (1) | IL247947B (enExample) |
| MX (1) | MX367914B (enExample) |
| WO (1) | WO2015144799A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6116782B1 (ja) * | 2015-08-28 | 2017-04-19 | 積水メディカル株式会社 | ベンジル化合物 |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| TW202016113A (zh) * | 2018-06-08 | 2020-05-01 | 大陸商貝達藥業股份有限公司 | Erk抑制劑及其應用 |
| JP7068743B2 (ja) * | 2019-01-11 | 2022-05-17 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物 |
| WO2020145369A1 (ja) * | 2019-01-11 | 2020-07-16 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN114315866B (zh) * | 2020-09-30 | 2023-10-31 | 烟台药物研究所 | 一种盐酸左旋咪唑的合成方法 |
| WO2022072634A1 (en) * | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| US20250276972A1 (en) * | 2020-12-15 | 2025-09-04 | Gritscience Biopharmaceuticals Co.,Ltd. | Compounds as casein kinase inhibitors |
| CN114957259A (zh) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | 氰基取代的芳香双环类化合物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| KR20040097375A (ko) | 2002-04-23 | 2004-11-17 | 시오노기 앤드 컴파니, 리미티드 | 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제 |
| KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
| AU2003297431A1 (en) * | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| JP2005343889A (ja) * | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| KR20100110815A (ko) | 2007-12-12 | 2010-10-13 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 살균제 이환식 피라졸 |
| CN101952293A (zh) | 2007-12-21 | 2011-01-19 | 惠氏有限责任公司 | 吡唑并[1,5-a]嘧啶化合物 |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| US8592432B2 (en) | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
| UY31750A (es) * | 2008-04-07 | 2009-12-14 | Irm Llc | Compuestos y composiciones como inhibidores de quinasa |
| EP2300469B1 (en) * | 2008-05-13 | 2015-06-24 | Novartis AG | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| CN102459264A (zh) * | 2009-05-27 | 2012-05-16 | 雅培制药有限公司 | 激酶活性的嘧啶抑制剂 |
| WO2010138579A1 (en) | 2009-05-28 | 2010-12-02 | Wilson-Cook Medical Inc. | Tacking device and methods of deployment |
| WO2011153553A2 (en) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| HK1198133A1 (en) | 2011-08-02 | 2015-03-13 | 辉瑞公司 | Crizotinib for use in the treatment of cancer |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
-
2015
- 2015-03-26 BR BR112016022105-2A patent/BR112016022105B1/pt active IP Right Grant
- 2015-03-26 CA CA2940918A patent/CA2940918C/en active Active
- 2015-03-26 JP JP2016559326A patent/JP6522646B2/ja active Active
- 2015-03-26 US US15/129,582 patent/US10280170B2/en active Active
- 2015-03-26 WO PCT/EP2015/056498 patent/WO2015144799A1/en not_active Ceased
- 2015-03-26 ES ES15713436T patent/ES2715676T3/es active Active
- 2015-03-26 KR KR1020167028572A patent/KR102455519B1/ko active Active
- 2015-03-26 EP EP15713436.2A patent/EP3129376B1/en active Active
- 2015-03-26 MX MX2016012668A patent/MX367914B/es active IP Right Grant
- 2015-03-26 EA EA201691930A patent/EA032255B1/ru not_active IP Right Cessation
- 2015-03-26 AU AU2015238296A patent/AU2015238296B2/en active Active
- 2015-03-26 CN CN201580016470.XA patent/CN106164076B/zh active Active
-
2016
- 2016-09-21 IL IL247947A patent/IL247947B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160137576A (ko) | 2016-11-30 |
| MX2016012668A (es) | 2016-12-14 |
| CA2940918C (en) | 2023-10-24 |
| EA032255B1 (ru) | 2019-04-30 |
| EP3129376B1 (en) | 2018-12-26 |
| EA201691930A1 (ru) | 2017-02-28 |
| IL247947B (en) | 2019-03-31 |
| BR112016022105B1 (pt) | 2023-01-31 |
| BR112016022105A2 (enExample) | 2017-08-15 |
| AU2015238296A1 (en) | 2016-09-08 |
| US10280170B2 (en) | 2019-05-07 |
| EP3129376A1 (en) | 2017-02-15 |
| CN106164076B (zh) | 2019-03-26 |
| US20170174690A1 (en) | 2017-06-22 |
| AU2015238296B2 (en) | 2018-10-18 |
| WO2015144799A1 (en) | 2015-10-01 |
| JP6522646B2 (ja) | 2019-05-29 |
| JP2017508779A (ja) | 2017-03-30 |
| CN106164076A (zh) | 2016-11-23 |
| KR102455519B1 (ko) | 2022-10-14 |
| ES2715676T3 (es) | 2019-06-05 |
| CA2940918A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016012668A (es) | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1. | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12016501963A1 (en) | Macrocyclic pyrimidine derivatives | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| ZA201803705B (en) | 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist | |
| MY198472A (en) | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| PH12016501962B1 (en) | Macrocyclic pyridine derivatives | |
| MX367913B (es) | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1. | |
| TN2017000524A1 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX375484B (es) | Derivados de azabencimidazol como inhibidores de pi3k beta | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| TW201613864A (en) | Novel compounds | |
| TN2017000384A1 (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors. | |
| MX2015014025A (es) | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| NZ740119A (en) | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | |
| MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |